Prevotella oris

(aka Bacteroides oris)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Prevotella oris, (aka Bacteroides oris), is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 8 gut microbiome compilation studies or metastudies. The DNA G+C content is 42-46%. Prevotella oris is a common gut coloniser. (Hahnke2016; Shah1990; Holdeman1982)



  • This organism has been recovered from the gingival sulcus of a patient with periodontitis. Also, from clinical sources (systemic infections) and chicken intestines. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • QUIRKS
  • In 94% of Europeans (unseenbio.com).
    • GENERAL CHARACTERISTICS (Hahnke2016); (Shah1990); (Holdeman1982);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; starch;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • 💧
  • Bile tolerance:
  • Few strains tolerate 10% bile
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; starch; lactose; maltose; raffinose; sucrose;
    • SPECIAL FEATURES (Hahnke2016); (Shah1990); (Holdeman1982);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; isobutyrate (trace); succinate (major); isovalerate (trace);
  • ✗
  • Metabolites not produced:
  • Hâ‚‚; indole;
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2013); (Citron2011); (Goldstein2006); (Goldstein2006c); (Citron2003); (Goldstein2003a); (Citron2001); (Goldstein2000a); (Goldstein1999b); (Holdeman1982);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; ertapenem; imipenem; meropenem; penicillin; piperacillin-tazobactam; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefoxitin;
  • ceftazidime;
  • Macrolides:
  • azithromycin; clarithromycin; erythromycin; quinupristin-dalfopristin; roxithromycin; telithromycin;
  • Tetracyclines:
  • doxycycline; tigecycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin; gemifloxacin; levofloxacin; moxifloxacin; ofloxacin; trovafloxacin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; ranbezolid; telithromycin;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Bacteroidetes Class:  Bacteroidia Order:  Bacteroidales Family:  Prevotellaceae Genus:  Prevotella Alt. name:  Bacteroides oris Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  the gingival sulcus of a patient with periodontitis. Also, from clinical sources (systemic infections) and chicken intestines
    DNA G+C(%):  42-46
    Bile reaction(%):  10(d(neg))
    		Aesculin:  + Starch:  + Milk:  curdle Meat:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Fructose:  + Glucose:  + Mannose:  + Lactose:  + Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  neg Starch:  + Erythritol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg G6PDH6PGDH:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Isobutyrate:  trace(+) Succinate:  Major(+) Isovalerate:  trace(+) H2:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Var(MIC50): ≤0.125, MIC90: 32, RNG: (≤0.0125-64)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.025-2)
    ampicillin:  S(MIC50): 0.125, MIC90: 4, RNG: (0.03–32)
    amp-sulb:  S(MIC50): 0.25, MIC90: 2, RNG: (0.12-4)
    penicillin:  S(MIC50): 0.06, MIC90: 8, RNG: (0.06–32)
    penicillin_G:  Var(MIC50): 0.5, MIC90: 8, RNG: (≤0.03-8)
    piper-taz:  S(MIC50): 0.015, MIC90: 0.06, RNG: (0.015–1)
    tica-clav:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.06–1)
    ertapenem:  S(0.125/0.25)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.016-0.125)
    meropenem:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–0.125)
    cefotaxime:  Var(MIC50): 2, MIC90: >32, RNG: (0.06–>32)
    cefoxitin:  S(MIC50): 1, MIC90: 4, RNG: (1-8)
    ceftazidime:  R(MIC50): 32, MIC90: >128, RNG: (1->128)
    cefuroxime:  Var(MIC50): 4, MIC90: >32, RNG: (0.125–>32)
    azithromycin:  S(MIC50): 1, MIC90: 8, RNG: (0.125–>32)
    erythromycin:  S(MIC50): 1, MIC90: 8, RNG: (0.125–32)
    clarithromycin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06–8)
    quin-dalf:  S(MIC50): 1, MIC90: 2, RNG: (≤0.0125-4)
    roxithromycin:  S(MIC50): 1, MIC90: 4, RNG: (0.06–8)
    telithromycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06–8)
    linezolid:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    ciprofloxacin:  S(MIC50): 2, MIC90: 8, RNG: (0.5-16)
    gatifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06-2)
    gemifloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.03-8)
    levofloxacin:  S(MIC50): 1, MIC90: 4, RNG: (0.5-16)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.03-2)
    ofloxacin:  S(MIC50): 1, MIC90: 8, RNG: (1-32)
    trovafloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.25–4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 8, RNG: (0.03–16)
    tigecycline:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.015–0.5)
    teicoplanin:  Var(MIC50): 2, MIC90: 16, RNG: (≤0.06->16)
    vancomycin:  R(MIC50): >16, MIC90: >16, RNG: (1->16)
    bacitracin:  Var(MIC50): 2, MIC90: 32, RNG: (0.5–32)
    chloramphenicol:  S(MIC50): 2, MIC90: 4, RNG: (1–8)
    metronidazole:  S(MIC50): 1, MIC90: 2, RNG: (≤0.125-2)
    ranbezolid:  S(MIC50): 0.03, MIC90: 0.125, RNG: (≤0.008-0.25)
    clindamycin:  S(MIC50): ≤0.016, MIC90: 0.016, RNG: (≤0.016->32)

    References

    SPECIFIC REFERENCES FOR PREVOTELLA ORIS
  • Hahnke2016 - Description of Proteiniphilum saccharofermentans sp. nov., Petrimonas mucosa sp. nov. and Fermentimonas caenicola gen. nov., sp. nov., isolated from mesophilic laboratory-scale biogas reactors, and emended description of the genus Proteiniphilum.
  • Shah1990 - Notes: Prevotella, a New Genus To Include Bacteroides melaninogenicus and Related Species Formerly Classified in the Genus Bacteroides.
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Citron2011 - In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • Holdeman1982 - Bacteroides oris and Bacteroides buccae New Species from Human Periodontitis and Other Human Infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PREVOTELLA ORIS
  • Bik2006 - Molecular analysis of the bacterial microbiota in the human stomach.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • Urban2020 - Altered Fecal Microbiome Years after Traumatic Brain Injury
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: January 14, 2022